Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

FDA appoints Toigo to replace Wood: FDA's Office of Special Health Issues Director Theresa Toigo is named acting director of the Office of Women's Health. Toigo, who has worked at the Center for Drug Evaluation & Research, the Center for Biologics Evaluation & Research and the Office of the Commissioner since 1984, will bring her experience as a liaison with patients and advocacy groups to her new post, where she will ensure that regulation remains "gender sensitive and responsive" and "work to correct any identified gender disparities in drug, device and biologics testing," according to a Sept. 16 release. On Aug. 31, former Women's Health Director Susan Wood resigned in protest over the agency's handling of Barr's Plan B emergency contraceptive (1"The Gray Sheet" Sept. 5, 2005, p. 6)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel